NASDAQ:HCM HUTCHMED H1 2026 Earnings Report $11.01 +0.05 (+0.46%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$11.03 +0.02 (+0.18%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast HUTCHMED EPS ResultsActual EPSN/AConsensus EPS $0.15Beat/MissN/AOne Year Ago EPSN/AHUTCHMED Revenue ResultsActual RevenueN/AExpected Revenue$304.16 millionBeat/MissN/AYoY Revenue GrowthN/AHUTCHMED Announcement DetailsQuarterH1 2026Date7/30/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile HUTCHMED Earnings HeadlinesHutchmed: Bullish On Their Commercial Prospects And Pipeline CatalystsJuly 19, 2026 | seekingalpha.comHUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET AmplificationJuly 2, 2026 | globenewswire.comBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.July 26 at 1:00 AM | Decentralized Masters (Ad)HUTCHMED to Announce 2026 Half-Year Financial ResultsJune 30, 2026 | globenewswire.comHUTCHMED's experimental drug shows durable responses in advanced bile duct cancer trialJune 25, 2026 | msn.comSyndio Acquires Embrace.aiJune 23, 2026 | businesswire.comSee More HUTCHMED Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HUTCHMED? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HUTCHMED and other key companies, straight to your email. Email Address About HUTCHMEDHUTCHMED (NASDAQ:HCM) (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market. HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer. Its clinical pipeline features both small molecules and monoclonal antibodies targeting receptor tyrosine kinases, immuno-oncology checkpoints and novel pathways, with ongoing trials in the United States, Europe and Asia. The company has established strategic partnerships and licensing collaborations with leading global pharmaceutical and biotechnology firms to co-develop and co-commercialize its assets. Founded in 2000 as Hutchison MediPharma and rebranded as HUTCHMED in 2018, the company is headquartered in Hong Kong, with research and development centers in Shanghai and Suzhou, China. HUTCHMED maintains commercial operations across mainland China and extends its clinical research infrastructure to the United States and Europe. Guided by an experienced leadership team with backgrounds in drug discovery, clinical development and commercial strategy, HUTCHMED continues to pursue its goal of delivering innovative medicines to patients worldwide.View HUTCHMED ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyDefense Earnings Show Readiness Now and Modernization AheadFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Upcoming Earnings Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
